Ray Therapeutics, a clinical-stage biopharmaceutical company headquartered in Berkeley, California, has announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to RTx-015, an optogenetic gene therapy delivered by single intravitreal injection, for the treatment of retinitis pigmentosa (RP). The designation follows a prior FDA Fast Track Designation for the same molecule, giving RTx-015 two concurrent expedited development pathways. RMAT status provides intensive FDA engagement during development and carries eligibility for priority review at the application stage, though priority review has not yet been granted.
RTx-015 encodes a light-sensitive protein delivered to retinal cells via intravitreal injection, with the goal of restoring light responsiveness independent of the patient’s underlying genetic mutation. The approach differs from most RP-directed gene therapies, which target specific causative mutations — a strategy that limits eligible patient populations to those carrying the relevant variant. By reprogramming surviving retinal cells rather than correcting a defined genetic defect, RTx-015 is designed to function across the heterogeneous mutational landscape of RP, which encompasses variants across more than 90 identified genes.
The therapy is currently being evaluated in the ENVISION trial (NCT06460844), a Phase I open-label dose-escalation study enrolling patients with RP or choroideremia. Up to three dose cohorts are planned, with participants followed for five years following a single injection. No clinical data from the ENVISION trial have been publicly disclosed. The RMAT designation was granted on the basis of preliminary clinical evidence, as required under the statutory criteria, though Ray Therapeutics has not disclosed which specific data package supported the application.
Research context
RP affects an estimated one in 4,000 individuals globally and involves progressive degeneration of rod and cone photoreceptors, typically leading to tunnel vision and eventual blindness. The condition is genetically heterogeneous, with autosomal dominant, autosomal recessive, and X-linked inheritance patterns all documented. That heterogeneity has historically constrained the gene therapy field: the only FDA-approved treatment for an inherited retinal dystrophy, voretigene neparvovec-rzyl (Luxturna, Spark Therapeutics), addresses only patients with biallelic RPE65 mutations — a fraction of the total RP population.
The optogenetic approach attempts to sidestep mutation-specific targeting by introducing a microbial opsin or engineered light-sensitive protein into remaining inner retinal neurons, rendering them light-responsive after photoreceptor loss. Gensight Biologics has advanced the furthest in this space with GS030, a ChrimsonR-based optogenetic construct evaluated in combination with light-stimulating goggles. Gensight reported partial visual recovery in a single patient in a 2021 Nature Medicine publication, though broader efficacy data from its Phase I/II trial remain limited. Applied Genetic Technologies Corporation (AGTC) and others have pursued mutation-specific approaches for RP subtypes including RPGR-linked X-linked RP, though several programs have encountered clinical setbacks.
Ray Therapeutics states that RTx-015 targets retinal cells without dependence on a specific mutation and does not require external light-amplification hardware, a design distinction from the Gensight approach. The press release does not disclose the specific opsin or transgene construct used, the viral vector, or the promoter driving expression. Those details, relevant to both the durability of expression and the immune profile of the therapy, have not been made public.
Your email address will not be published. Required fields are marked *
Comment *
Name *
Email *
Website
